RxDoctor Payments Data

Melissa Russell

Family · New York, NYNPI 1740628106

Payments from drug & device makers

$6,422in general payments, 2019–2025

Across 122 payments — averaging $52.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$4K
  • Harmony Biosciences LLC$783
  • Avadel CNS Pharmaceuticals, LLC$701
  • Axsome Therapeutics, Inc.$227
  • Lilly USA, LLC$167
  • Inspire Medical Systems, Inc.$97
  • plus $277 from 5 others

What the payments were for

  • Speaking & faculty fees$2,58040%
  • Travel & lodging$62710%
  • Food & beverage$3,08048%
  • Education$1352%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,422 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$29,418
Medicare patients
168
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate26$25,272
QuviviqDaridorexant Hcl37$17,907
SunosiSolriamfetol Hcl18$16,785
BelsomraSuvorexant37$15,462
Levetiracetam ErLevetiracetam11$2,152
Doxepin Hcl29$2,058
Divalproex Sodium ErDivalproex Sodium13$1,820
Ramelteon18$1,610
Zaleplon59$1,564
Gabapentin91$1,001
Modafinil27$996
Quetiapine Fumarate26$743
Pramipexole DihydrochloridePramipexole Di-Hcl13$607
Zolpidem Tartrate62$577
Clonazepam54$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$63$25,27226 claims
Idorsia Pharmaceuticals US IncQuviviq$94$17,90737 claims
Axsome Therapeutics, Inc.Sunosi$227$16,78518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →